DENVER, Oct. 3, 2017 /PRNewswire/ -- One of the leading factors in research study delays is lack of enrollment. Over 94 percent of cancer clinical trials are behind scheduled enrollment timelines and the cost associated with those delays are in the tens of millions of dollars for larger programs. Low enrollment numbers can be contributed to a much larger problem: a lack of communication between oncologists.
ClinicalTrial.gov is currently the primary source of clinical trial listings available to oncologists, however, this source lacks ease of use and the ability to accurately search study information. The information at this source lacks consistent structure for searching disease specifics, line of therapy, I/E Criteria, or molecular target when applicable.
When an oncologist finally identifies a clinical trial for their patient on ClinicalTrial.gov, the second major challenge is identifying the right coordinator at the closest site to learn more about the study and commence the patient referral process. A large portion of clinical trial sponsors blind the research site, essentially hiding the identify and location of actual research site. Additionally, many of these sites manage hundreds of studies at once, making it even more difficult to find the right study coordinator for the right study. Oncologists cannot waste time navigating outdated systems, when they could be using that time to conduct more trials and move the drug development process forward.
With ClinOne's referral network technology, a study can reach hundreds of nearby oncologists at once by identifying location, disease, and specialist details. Once an oncologist (or other referring physician) has been invited to refer to the study, they can refer patients within seconds of accessing ClinOne mobile and web-interface. Referring oncologists are also provided with high-level screening information to pre-screen the patient prior to contacting the open site, significantly increasing the likelihood of a patient match.
ClinOne's referral technology has proven to increase enrollment by over 90 percent and it will increase clinical trial enrollment by 10-fold over the next two years. "If we simply use the power of our oncology community to identify specific targets of cancer patients to enroll into a clinical trial, we can absolutely rethink how we enroll patients into these potentially life-saving clinical trials. We must start rethinking how we accelerate the drug development process," stated Rob Bohacs, ClinOne CEO.
About ClinOne, Inc.
Based in Denver, Colorado, ClinOne is a mobile technology company dedicated to transitioning research into a mobile environment to significantly improve how researchers and patients interact and engage with clinical trials. The company offers a full suite of mobile technologies to centralize research and deliver the needed clinical trial content to the right participants. ClinOne information platform aims to improve day-to-day engagement of clinicians, academic researchers, drug developers, and patients to help advance drug and medical device clinical trials.
For more information, please visit www.ClinOne.com.
SOURCE ClinOne, Inc.